This is a contrast between Eyenovia Inc. (NASDAQ:EYEN) and Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) based on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyenovia Inc.	N/A	0.00	17.25M	-1.43	0.00
Ampio Pharmaceuticals Inc.	N/A	0.00	33.99M	-0.23	0.00

Table 1 demonstrates Eyenovia Inc. and Ampio Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both businesses.

	Net Margins	Return on Equity	Return on Assets
Eyenovia Inc.	0.00%	-70.4%	-66.2%
Ampio Pharmaceuticals Inc.	0.00%	-489.2%	381%

Liquidity

The Current Ratio and a Quick Ratio of Eyenovia Inc. are 12.3 and 12.3. Competitively, Ampio Pharmaceuticals Inc. has 5.3 and 5.3 for Current and Quick Ratio. Eyenovia Inc.’s better ability to pay short and long-term obligations than Ampio Pharmaceuticals Inc.

Insider & Institutional Ownership

Institutional investors held 10% of Eyenovia Inc. shares and 24.5% of Ampio Pharmaceuticals Inc. shares. About 2.1% of Eyenovia Inc.’s share are held by insiders. Comparatively, insiders own roughly 0.5% of Ampio Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Eyenovia Inc.	2%	45.71%	54.55%	0.79%	-44.5%	78.95%
Ampio Pharmaceuticals Inc.	5.89%	36.92%	8.61%	8.68%	-68.31%	73.4%

For the past year Eyenovia Inc.’s stock price has bigger growth than Ampio Pharmaceuticals Inc.

Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst that has completed Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat that has completed Phase II clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.